A phase 3B, multicenter, open-label study investigating the clinical utility and safety of pramlintide in subjects with type 1 and type 2 diabetes mellitus who have not achieved glycemic targets with insulin therapy
Phase of Trial: Phase III
Latest Information Update: 28 May 2015
At a glance
- Drugs Pramlintide (Primary)
- Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Amylin Pharmaceuticals
- 31 Aug 2018 Biomarkers information updated
- 11 Feb 2013 Actual end date added as 1 Jun 2005 as reported by ClinicalTrials.gov.
- 01 Oct 2005 New trial record.